Participated · Series D · Jan 2026

Cellares builds and operates fully automated platforms for cell therapy manufacturing, including the Cell Shuttle for end-to-end manufacturing and Cell Q for automated in-process and release quality control. The company says its automation delivers industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10× more cell therapy batches than conventional CDMOs with comparable footprint and headcount. The Cell Shuttle has received the FDA's Advanced Manufacturing Technology (AMT) designation and the company reports a 100% automation success rate across more than a dozen automated processes. Cellares has achieved clinical validation milestones such as a successful IND amendment enabling active clinical manufacturing on the Cell Shuttle and the dosing of first patients in a partner clinical trial across multiple therapeutic areas and modalities. Headquartered in South San Francisco, Cellares operates a commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, and has additional facilities under construction in Europe and Japan. The company is positioning its network of IDMO Smart Factories to support both clinical and commercial programs and to expand access to cell therapies worldwide.

Participated · Series B · Jan 2026

Kinaset Therapeutics is focused on creating inhaled, anti-inflammatory medicines for serious respiratory conditions. Its lead candidate, frevecitinib, is a dry-powder, single-capsule pan-JAK inhibitor (JAK1/2/3, TYK2) designed to deliver therapeutic lung concentrations while minimizing systemic exposure. The drug targets both Th2- and Th1-driven disease, giving it potential efficacy across the broad severe asthma population, including patients with non-eosinophilic phenotypes who currently lack effective options. Early clinical data have demonstrated promising safety and pharmacology, and proceeds from the latest financing will fund a Phase 2 dose-ranging study in severe asthma patients. By overcoming historical drug-delivery challenges for inhaled JAK inhibitors, Kinaset aims to provide the first novel, inhaled anti-inflammatory mechanism for asthma in decades. The company operates from Boston and is supported by a syndicate of leading life-science investors.

Participated · Series B · Nov 2025

AAVantgarde Bio is advancing best-in-class AAV gene therapies aimed at treating severe inherited retinal diseases (IRDs) that currently have no approved therapies. Its lead candidate, AAVB-039, is being evaluated in the CELESTE study to address Stargardt disease caused by ABCA4 mutations, alongside the >100-patient STELLA natural history study. A second program, AAVB-081, is in a Phase 1/2 LUCE trial for retinitis pigmentosa secondary to Usher syndrome type 1B arising from MYO7A mutations. Led by CEO Dr. Natalia Misciattelli, the company plans to use newly secured capital to achieve clinical proof-of-concept for both programs. The pipeline positions AAVantgarde to enter mid-stage development in two large, unmet IRD markets. Financially, the company has just closed a substantial $141 million Series B round to fund these milestones, underscoring strong investor confidence in its platform. No revenue or patient adoption metrics have yet been disclosed, consistent with its clinical-stage status.

Participated · Series A · Jun 2025

Antares Therapeutics applies a proprietary covalent discovery engine—including proprietary screening libraries, chemoproteomics, structure‑guided computational chemistry and machine‑learning tools—to identify challenging, high‑value oncology targets. The company will lead discovery work on a limited set of historically undruggable targets under a collaboration with Novartis while continuing to advance its owned and partnered portfolio of precision cancer and other serious‑disease medicines. Financially, the collaboration provided a $105 million upfront payment and the potential for up to $1.8 billion in additional milestone payments and tiered royalties if programs progress and commercialize. The partnership is intended to pair Antares’ discovery capabilities with Novartis’ development and global commercialization resources to accelerate translation of its science into therapies.

Led · Series B · Nov 2024

Robin AI leverages generative AI to automate contract drafting and negotiation and to extract information from large contract repositories. Its flagship product, Robin Reports, analyzes and summarizes thousands of legal documents to provide insights for M&A and incident response. Founded in 2019 by Richard Robinson and James Clough, Robin AI is London-based and has offices in New York, London, and Singapore. Its client roster includes UBS, GE, Pfizer, AbbVie, PepsiCo, KPMG, PwC, and Blue Origin. The company grew its U.S. operations six-fold in 2024 and will use the new funds to support rapid growth in the U.S. market and continued expansion within the global enterprise sector. Financially, Robin AI has raised $25M in this Series B, bringing total funding to $61.5M to date. Robin AI provides an AI-powered legal copilot that automates and speeds up drafting, negotiating, and extracting information from contracts. Its product is available as a Microsoft Word add-in and is reported to cut contract review time by 85%. The company operates a hybrid model combining Anthropic’s Claude LLM with its own proprietary contract data from over 2 million contracts and in-house machine learning. An in-house team of legal professionals (lawyers-in-the-loop) refines outputs to ensure quality and accuracy. Robin AI serves customers ranging from large multinationals to SMEs and scaleups and derives three quarters of its revenue from the US. The company plans to expand its US on-the-ground team, open an office in Singapore to enter Asia Pacific, and grow its AI and machine-learning team. Robin AI builds a "lawyer-in-the-loop" generative AI platform for contract generation, editing and automated processing, offered via a freemium self-serve tier for SMEs and more advanced tools for high-volume bespoke agreements. The product couples fine-tuned LLMs (trained on a proprietary dataset of over 7 million legal text data points) with an in-house legal team of about 30 qualified lawyers to maintain quality and accountability. The company has around 75 full-time employees and is led by CEO Richard Robinson, a former barrister, alongside co-founder James Clough, a former research scientist. Robin AI primarily deploys in the US, which accounts for roughly three-quarters of its revenue, and says revenue has grown about 20-fold since its prior fundraise. The team is pursuing M&A to extend product reach and used part of the latest round to partially acquire competitor LawGeex. The platform is marketed at a mix of customers from SMEs to large global corporations.